These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10957771)

  • 41. [Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1-10 ng/ml].
    Fujinami K; Miura T; Takizawa A; Osada Y; Kawakami S
    Nihon Hinyokika Gakkai Zasshi; 2005 May; 96(4):475-9. PubMed ID: 15948407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical usefulness of free PSA fraction as an indicator of prostate cancer.
    Filella X; Alcover J; Molina R; Giménez N; Rodríguez A; Jo J; Carretero P; Ballesta AM
    Int J Cancer; 1995 Dec; 63(6):780-4. PubMed ID: 8847133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate cancer and prostate-specific antigen: the more we know, the less we understand.
    Thompson I; Leach RJ; Pollock BH; Naylor SL
    J Natl Cancer Inst; 2003 Jul; 95(14):1027-8. PubMed ID: 12865440
    [No Abstract]   [Full Text] [Related]  

  • 44. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.
    McDonald ML; Parsons JK
    Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum proteomic patterns for detection of prostate cancer.
    Petricoin EF; Ornstein DK; Paweletz CP; Ardekani A; Hackett PS; Hitt BA; Velassco A; Trucco C; Wiegand L; Wood K; Simone CB; Levine PJ; Linehan WM; Emmert-Buck MR; Steinberg SM; Kohn EC; Liotta LA
    J Natl Cancer Inst; 2002 Oct; 94(20):1576-8. PubMed ID: 12381711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma.
    Dalkin BL; Ahmann FR; Kopp JB; Catalona WJ; Ratliff TL; Hudson MA; Richie JP; Scardino PT; Flanigan RC; Dekernion JB
    Br J Urol; 1995 Sep; 76(3):346-50. PubMed ID: 7551844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
    Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
    J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project.
    Kane RA; Littrup PJ; Babaian R; Drago JR; Lee F; Chesley A; Murphy GP; Mettlin C
    Cancer; 1992 Mar; 69(5):1201-7. PubMed ID: 1371234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biomarkers for early prostate cancer detection.
    Margreiter M; Stangelberger A; Valimberti E; Herwig R; Djavan B
    Minerva Urol Nefrol; 2008 Mar; 60(1):51-60. PubMed ID: 18427435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostatic specific antigen. From its early days until becoming a prostate cancer biomarker.
    Dellavedova T
    Arch Esp Urol; 2016; 69(1):19-23. PubMed ID: 26856734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The significance of early detection for prostate cancer in mass screening].
    Kato M; Tammbo M; Yoshimatsu T; Ohta M; Kinjyo M; Noda H; Watanabe K; Miyata A; Murata A; Miura I; Yoneda T; Yoshii M; Okegawa T; Kojima M; Sayama T; Nutahara K; Higashihara E
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):23-9. PubMed ID: 11235139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of serum level of prostate-specific antigen adjusted for the transition zone volume in early detection of prostate cancer.
    Ferreira MD; Koff WJ
    Int Braz J Urol; 2005; 31(2):137-45; discussion 146. PubMed ID: 15877833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PSA and the detection of prostate cancer.
    Robbins AS
    JAMA; 1994 Jan; 271(3):192-3. PubMed ID: 7506314
    [No Abstract]   [Full Text] [Related]  

  • 54. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New serum markers in prostate carcinoma and their application to artificial neural networks].
    Stephan C; Jung K; Cammann H; Kramer J; Kristiansen G; Loening SA; Lein M
    Urologe A; 2007 Sep; 46(9):1084-6. PubMed ID: 17641867
    [No Abstract]   [Full Text] [Related]  

  • 56. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
    Magri V; Trinchieri A; Montanari E; Del Nero A; Mangiarotti B; Zirpoli P; de Eguileor M; Marras E; Ceriani I; Vral A; Perletti G
    Arch Ital Urol Androl; 2007 Jun; 79(2):84-92. PubMed ID: 17695414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and discriminative ability of prostate-specific antigen as a tumor marker.
    Leitenberger A; Altwein JE
    Eur Urol; 1990; 17(1):12-6. PubMed ID: 1690653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    D'Amico AV
    J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
    [No Abstract]   [Full Text] [Related]  

  • 59. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. II. Rectal palpation, PSA, and transrectal echography].
    Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Gómez dos Santos V; García González R
    Arch Esp Urol; 1997 May; 50(4):339-45. PubMed ID: 9313042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle].
    Luboldt HJ; Altwein JE; Bichler KH; Czaja D; Hüsing J; Fornara P; Jöckel KH; Lübben G; Schalkhäuser K; Weissbach L; Wirth M; Rübben H
    Urologe A; 1999 Mar; 38(2):114-23. PubMed ID: 10231930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.